Cargando…

ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin

EGFR is required for animal development, and dysregulation of EGFR is critically implicated in malignant transformation. However, the molecular mechanism underlying the regulation of EGFR expression remains poorly explored. Here we report that the zinc-finger protein ZNF516 is a transcription repres...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lifang, Liu, Xinhua, He, Lin, Yang, Jianguo, Pei, Fei, Li, Wanjin, Liu, Shumeng, Chen, Zhe, Xie, Guojia, Xu, Bosen, Ting, Xia, Zhang, Zihan, Jin, Tong, Liu, Xujun, Zhang, Wenting, Yuan, Shuai, Yang, Ziran, Wu, Chongyang, Zhang, Yu, Yang, Xiaohan, Yi, Xia, Liang, Jing, Shang, Yongfeng, Sun, Luyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612949/
https://www.ncbi.nlm.nih.gov/pubmed/28947780
http://dx.doi.org/10.1038/s41467-017-00702-5
Descripción
Sumario:EGFR is required for animal development, and dysregulation of EGFR is critically implicated in malignant transformation. However, the molecular mechanism underlying the regulation of EGFR expression remains poorly explored. Here we report that the zinc-finger protein ZNF516 is a transcription repressor. ZNF516 is physically associated with the CtBP/LSD1/CoREST complex and transcriptionally represses a cohort of genes including EGFR that are critically involved in cell proliferation and motility. We demonstrate that the ZNF516–CtBP/LSD1/CoREST complex inhibits the proliferation and invasion of breast cancer cells in vitro and suppresses breast cancer growth and metastasis in vivo. Significantly, low expression of ZNF516 is positively associated with advanced pathological staging and poor survival of breast carcinomas. Our data indicate that ZNF516 is a transcription repressor and a potential suppressor of EGFR, adding to the understanding of EGFR-related breast carcinogenesis and supporting the pursuit of ZNF516 as a potential therapeutic target for breast cancer.